Media headlines about Loxo Oncology (NASDAQ:LOXO) have been trending positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Loxo Oncology earned a media sentiment score of 0.27 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.3434640390946 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

Loxo Oncology (NASDAQ:LOXO) opened at $92.23 on Friday. Loxo Oncology has a 52-week low of $40.01 and a 52-week high of $106.40. The firm has a market capitalization of $2,717.13, a price-to-earnings ratio of -15.82 and a beta of 2.57.

A number of research analysts have recently weighed in on LOXO shares. BidaskClub upgraded Loxo Oncology from a “strong sell” rating to a “sell” rating in a research report on Tuesday, December 12th. Citigroup dropped their price target on Loxo Oncology from $112.00 to $108.00 and set a “buy” rating for the company in a research report on Thursday, November 16th. JMP Securities upgraded Loxo Oncology from a “market perform” rating to an “outperform” rating and raised their price target for the company from $77.18 to $95.00 in a research report on Tuesday, November 14th. Ifs Securities upgraded Loxo Oncology from an “outperform” rating to a “strong-buy” rating in a research report on Tuesday, November 14th. Finally, Zacks Investment Research cut Loxo Oncology from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $97.33.

In other news, Director Orbimed Advisors Llc sold 270,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $74.26, for a total value of $20,050,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Aisling Capital Iii Lp sold 500,000 shares of the firm’s stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $75.00, for a total value of $37,500,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,628,396 shares of company stock valued at $125,989,430. Company insiders own 44.40% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Positive Press Coverage Somewhat Unlikely to Affect Loxo Oncology (LOXO) Share Price” was first published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at

About Loxo Oncology

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with's FREE daily email newsletter.